fda semaglutide warning november 2025 FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

The Therapeutic Goods Administration has issued an urgent safety warning over the risk of suicidal thoughts linked to popular drugs used to treat type 2 diabetes and obesity. The affected drugs include: -

29.18

★★★★☆4.8 (126)

FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in the U.S. drug supply chain. The agency recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg that were

23.96

★★★★★4.9 (98)

Ozempic Lawsuits: Possible Compensation For Damages

23.32

★★★★★5.0 (157)

FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain

25.53

★★★★★4.7 (84)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

24.39

★★★★★4.9 (203)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

21.32

★★★★★5.0 (176)

Compounded "semaglutide" is not FDA-approved

24.89

★★★★★4.8 (132)